Orphanet Journal of Rare Diseases | Adult Adrenoleukodystrophy Patients and Caregivers’ Perspectives on Disease Burden and Treatment Needs

Recommend:

This study comprehensively reveals the disease burden and treatment needs of adult ALD from the perspectives of patients and caregivers, emphasizing the urgency of developing disease-specific therapies and providing important patient-focused evidence for future clinical trial design.

 

Literature Overview

The article entitled 'Living with adrenoleukodystrophy: adult patient and caregiver perspectives' published in Orphanet Journal of Rare Diseases reviews and summarizes the key outcomes of the External-Led Patient-Focused Drug Development meeting (EL-PFDD) organized by ALD Connect. It includes feedback data from 254 participants (patients, caregivers, physicians, pharmaceutical representatives, etc.). The study demonstrates that patients and caregivers offer detailed firsthand information regarding disease symptoms, current treatment landscape, and future needs, highlighting the limitations of existing therapies in symptom management and the strong patient desire to participate in new drug development and clinical trials.

Background

Adrenoleukodystrophy (ALD) is an X-linked genetic disorder caused by mutations in the ABCD1 gene, leading to the accumulation of very long-chain fatty acids in the body and affecting central nervous system and adrenal function. The clinical manifestations of ALD are highly heterogeneous, including three main phenotypes: chronic progressive myelopathy (AMN), rapidly progressive cerebral leukodystrophy (cALD), and primary adrenal insufficiency. Males typically exhibit more severe symptoms, while females are often carriers, though approximately 80% of female carriers eventually develop spinal cord symptoms. Currently, no effective treatment exists for adult ALD, and only supportive measures are available. Research efforts are focused on gene therapy, small molecule drugs (e.g., leriglitazone), and early disease screening, but adult ALD treatment faces significant challenges such as high heterogeneity, lack of unified disease models, and difficulties in patient recruitment. The EL-PFDD meeting was specifically designed to address the absence of patient voices in drug development and its findings will provide critical insights for regulatory and pharmaceutical decision-making.

 

A practical tool for rapidly aligning DNA or RNA sequences to the genome, suitable for genomic comparison and sequence analysis.

Learn More

 

Research Methods and Experiments

The study was conducted through the External-Led Patient-Focused Drug Development (EL-PFDD) meeting organized by ALD Connect, which invited participants including patients, caregivers, physicians, pharmaceutical companies, and regulatory representatives. Online surveys and live discussions were used to gather feedback from patients and caregivers regarding symptoms, current treatment, and future needs. The meeting was held via Zoom on July 22, 2022, with 254 total participants, of which 153 were patients or caregivers. Real-time voting and live interviews collected multi-dimensional data on disease burden, treatment effectiveness, and expectations, which were then discussed in the context of clinical research advancements.

Key Findings and Perspectives

• 81% of patients reported balance issues, 67% reported gait abnormalities and spasms, 69% experienced walking difficulties due to the disease, 45% could not participate in sports, and 41% suffered from sleep disturbances
• 88% of patients expressed concern about disease progression, 61% feared losing the ability to walk, 39% worried about developing cALD, and some patients voiced concerns about family relationships, employment, and independent living
• No specific treatment is available for adult ALD. Patients use vitamins, antispasmodics, painkillers, CBD, and similar compounds, but only 38% and 44% reported minimal or partial relief, respectively, while 10% experienced no relief
• Patients strongly desire to participate in clinical trials, with 18% having previously participated. Some female patients expressed a wish to be included in research to accelerate therapeutic development
• Although drugs like leriglitazone show promise in delaying disease progression in early-stage cALD, treatment research for AMN remains limited. Future studies should re-evaluate clinical endpoints and incorporate data from female patients

Significance and Future Directions

The study underscores the central role of patients and caregivers in rare disease treatment development, offering real-world insights into patient needs for pharmaceutical and regulatory bodies. The findings will help guide future ALD drug development by focusing on walking ability, disease progression, and prevention of cALD, and suggest innovative clinical trial designs (e.g., placebo-free, real-world data, remote follow-ups) to improve efficiency. Furthermore, female patients—who are often overlooked—face significant psychological and caregiving burdens, and deserve greater attention in treatment and support systems.

 

Enter a gene to view its associated signaling pathways and known upstream/downstream molecules, offering insights into gene function and regulatory networks.

Learn More

 

Conclusion

This study systematically captured the lived experiences of adult adrenoleukodystrophy (ALD) patients and caregivers through the EL-PFDD meeting, revealing the profound impact of ALD on quality of life, mental health, and daily activities. Patients widely reported limited efficacy of current treatments and expressed a strong desire for therapies that can slow or halt disease progression, as well as opportunities to participate in clinical trials. The findings provide essential patient-centered data for future drug development and regulatory decision-making, emphasizing the need to include a broader representation of ALD patients—including females—in therapeutic research. The study also highlights limitations in current clinical trial designs regarding recruitment, endpoint definitions, and gender inclusivity. As global attention to rare disease therapies increases, patient-centered studies like this will play a pivotal role in guiding disease management and drug discovery.

 

Amena Smith Fine, Kathleen O’ Sullivan-Fortin, Kelly Miettunen, Ali Fatemi, and Florian Eichler. Living with adrenoleukodystrophy: adult patient and caregiver perspectives. Orphanet Journal of Rare Diseases.